Medications to Treat Alzheimer’s Disease: Examples and Financial Help

Alzheimer’s treatment has entered a new era. For years, the conversation was mostly about medicines that could temporarily ease symptoms. Helpful? Yes. Miraculous? Sadly, no. Now the menu is a little bigger and a little more complicated, with newer drugs that may slow disease progression for some people, older drugs that still play an important role, and a billing maze that can make even a calm adult want to lie down on the kitchen floor and stare at the ceiling.

That is exactly why families need a practical guide. If you or someone you love is living with Alzheimer’s disease, the big questions usually sound like this: Which medications are available? What do they actually do? Who are they for? What side effects matter? And maybe the loudest question of all: how on earth do people pay for this?

This guide breaks down the main medications used to treat Alzheimer’s disease, including symptom-managing drugs, newer anti-amyloid treatments, and one medication approved for agitation related to Alzheimer’s dementia. It also covers financial help options, from Medicare and patient assistance programs to counseling services that can help families compare plans and lower out-of-pocket costs.

Important note: This article is for educational purposes only and is not a substitute for personal medical advice. Alzheimer’s treatment decisions should always be made with a qualified clinician who knows the patient’s diagnosis, stage of disease, MRI findings, other medications, and overall health.

What Alzheimer’s medications can and cannot do

Let’s start with the truth, because Alzheimer’s treatment is hard enough without sugar coating. No currently approved medication cures Alzheimer’s disease. Instead, today’s drugs generally fall into two buckets.

The first bucket includes medications that help manage symptoms such as memory problems, confusion, or daily functioning. These drugs may help some people stay steadier for a while, but they do not stop the disease itself.

The second bucket includes newer anti-amyloid therapies that target one of the biological hallmarks of Alzheimer’s disease. These medicines are not for everyone, and they come with monitoring requirements and meaningful risks, but they may slow decline in selected patients with early Alzheimer’s.

In plain English: some medications help the brain work a bit better for a time, and some try to slow part of the disease process. Neither category is a magic wand, but both can matter.

Main medications used to treat Alzheimer’s disease

1. Donepezil

Donepezil is one of the best-known Alzheimer’s medications. It is a cholinesterase inhibitor, which means it helps preserve acetylcholine, a brain chemical involved in memory and thinking. It is commonly used for mild, moderate, and severe Alzheimer’s disease.

Brand examples include Aricept and the once-weekly donepezil patch Adlarity. Families often like donepezil because it is familiar to clinicians, available in generic oral form, and commonly used as a first medication after diagnosis.

Typical issues include nausea, diarrhea, sleep disturbance, muscle cramps, fatigue, and weight loss. For some people, those side effects are manageable. For others, they are the reason dinner suddenly becomes a negotiation with toast and applesauce.

2. Rivastigmine

Rivastigmine is another cholinesterase inhibitor. It is used for mild to moderate Alzheimer’s disease and comes as capsules, liquid, and a skin patch. The patch version is often helpful for people who have trouble swallowing pills or who get stomach upset with oral medications.

Brand examples include Exelon and Exelon Patch. The patch can be especially useful in caregiving situations where daily pill battles have become a full-contact sport.

Common concerns include nausea, vomiting, decreased appetite, weight loss, and, with the patch, skin reactions at the application site.

3. Galantamine

Galantamine is also a cholinesterase inhibitor and is typically used for mild to moderate Alzheimer’s disease. It can help with memory and thinking symptoms for some patients, though results vary from person to person.

Brand examples include Razadyne, and newer galantamine-related branded options may also come up in current treatment discussions. As with the rest of this medication class, it is a “helpful for some, not dramatic for all” kind of medicine.

Common side effects may include nausea, vomiting, diarrhea, reduced appetite, dizziness, and headache.

4. Memantine

Memantine works differently. It is an NMDA receptor antagonist and is generally prescribed for moderate to severe Alzheimer’s disease. Rather than boosting acetylcholine, it affects glutamate signaling, another brain communication pathway.

Brand examples include Namenda and Namenda XR. Memantine may help some people maintain certain daily abilities a little longer, especially in later stages of the disease.

Side effects are often different from the cholinesterase inhibitors and may include dizziness, confusion, constipation, or headache. Some people tolerate memantine better than they tolerate the older symptom drugs, which can make it a practical option.

5. Memantine plus donepezil

Some patients take memantine and donepezil together. There is also a combination product called Namzaric, which combines extended-release memantine with donepezil in one capsule. This is generally used for moderate to severe Alzheimer’s disease in patients already stabilized on donepezil.

The combination approach is not about getting cute with the pill organizer. It is about using two different mechanisms in an attempt to support cognition and daily function from more than one angle.

6. Lecanemab

Lecanemab, sold as Leqembi, is one of the newer anti-amyloid therapies. It is intended for people with early Alzheimer’s disease, usually those with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, with confirmed amyloid pathology.

This drug is important because it aims to modify disease biology, not just symptoms. In selected patients, it may slow cognitive decline. That said, it is not appropriate for every person with Alzheimer’s disease, and it requires careful screening and follow-up.

The biggest safety issue is amyloid-related imaging abnormalities, often called ARIA. ARIA can involve swelling or bleeding in the brain, and that is why MRI monitoring is part of the process. This is not a “grab a prescription and circle back next year” medication.

7. Donanemab

Donanemab, sold as Kisunla, is another anti-amyloid treatment for early Alzheimer’s disease. Like lecanemab, it is used in carefully selected patients and is tied to monitoring requirements because ARIA is a real risk.

Families sometimes hear about these drugs and assume they are new versions of older memory pills. They are not. These treatments live in a different category, often involve infusion-based care, and can trigger a very different coverage conversation with insurers and Medicare.

8. Brexpiprazole for agitation related to Alzheimer’s dementia

Although it does not treat the underlying Alzheimer’s disease itself, brexpiprazole (Rexulti) deserves a brief mention because it became the first FDA-approved treatment for agitation associated with dementia due to Alzheimer’s disease.

That matters because agitation can be one of the most disruptive and exhausting parts of care. Pacing, verbal aggression, restlessness, and physical aggression can upend home life, strain relationships, and raise the risk of emergency visits or facility placement.

Brexpiprazole is not a casual add-on and is not approved as an as-needed calming pill. It requires careful prescribing and ongoing reassessment, especially in older adults who may already be medically fragile.

How doctors decide which medication may fit

Choosing an Alzheimer’s medication is not just about stage of disease. Clinicians also look at swallowing ability, appetite, heart rhythm concerns, fall risk, kidney function, MRI findings, caregiver support, infusion access, insurance coverage, and how much monitoring a family can realistically manage.

For example, a person with early Alzheimer’s and confirmed amyloid plaques may be a candidate for lecanemab or donanemab. A person with more advanced disease may be more likely to receive donepezil, memantine, or combination therapy. A person who cannot tolerate oral medications may do better with a patch. A person with distressing agitation may need a different conversation entirely.

In other words, the right medication is often less about the flashiest headline and more about the full real-life picture.

Common side effects and safety issues families should know

Most Alzheimer’s medications can cause side effects, especially during the first few weeks or after dose increases. Cholinesterase inhibitors commonly cause stomach upset, diarrhea, decreased appetite, sleep trouble, and weight loss. Memantine may cause dizziness or confusion. Anti-amyloid drugs carry the special concern of ARIA, which is why imaging and follow-up matter so much.

Families should also watch for practical red flags: sudden worsening confusion, repeated vomiting, major appetite loss, falls, fainting, new headaches, or neurological changes. These are not “wait and see for six months” issues. They deserve a call to the care team.

Another important point: more medication is not always better. Doctors often start low and increase slowly because a small benefit with acceptable side effects is usually better than an ambitious dose that wrecks sleep, appetite, and dignity in one dramatic week.

Financial help for Alzheimer’s medications

Now for the part that makes families reach for a spreadsheet, a calculator, and maybe a stress snack. Alzheimer’s medication costs can vary wildly depending on whether the drug is a generic tablet, a branded patch, or a newer infused therapy with testing and monitoring attached.

Medicare Part D for pills and patches

Many oral Alzheimer’s drugs and patches are handled through Medicare Part D or a Medicare Advantage plan with drug coverage. That means families should check the plan’s formulary, tier placement, prior authorization rules, and any step therapy requirements. During open enrollment, switching plans may reduce costs if the current plan is stingy with coverage.

Older drugs are often easier to place within a standard prescription plan than newer specialty treatments. Still, the details matter. A drug may be covered on paper but still sit on a tier that makes your wallet flinch.

Medicare Part B and registry requirements for anti-amyloid therapy

For anti-amyloid monoclonal antibodies like Leqembi and Kisunla, Medicare coverage is more specific. Eligible patients generally need a diagnosis of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, documented amyloid evidence, and a clinician participating in a qualifying registry or study process. That is a very different path from filling a prescription at the neighborhood pharmacy.

Families should also remember that costs may include more than the drug itself. MRI monitoring, infusion-related care, specialist visits, and diagnostic testing can all shape the final bill.

Extra Help for Medicare prescription costs

The federal Extra Help program can significantly reduce Medicare Part D costs for people with limited income and resources. This can help with premiums, deductibles, and copays. In 2026, people who qualify can have very low copays for covered drugs, and once qualifying drug costs reach the annual threshold, covered prescriptions can drop to zero cost for the rest of the year.

If a family member may qualify, it is worth applying. This is one of those programs that sounds bureaucratic until it starts saving real money, at which point it becomes the most beautiful paperwork on earth.

The Medicare Prescription Payment Plan

Another option is the Medicare Prescription Payment Plan, which can spread out out-of-pocket prescription costs across the year. This does not lower the total amount owed, but it can make monthly expenses easier to manage, especially for people facing a large bill early in the year.

Manufacturer patient assistance programs

Drug manufacturers may offer their own support programs. For example, the LEQEMBI Companion and Eisai Patient Assistance Program provide support with coverage questions and may offer free drug to eligible uninsured or financially burdened patients who meet program rules.

For Kisunla, Lilly offers support resources and a savings card program for eligible commercially insured patients. Lilly also has the Lilly Cares patient assistance pathway for certain medications and eligible people with financial need. As always, program terms can change, so families should confirm current eligibility rules directly.

Free counseling and search tools

Families do not have to decode all of this alone. Helpful resources include:

• SHIP counselors, who provide one-on-one Medicare guidance and can help compare plans or identify assistance programs.
• America’s Medicines, a search tool that helps patients and caregivers find manufacturer-sponsored support resources.
• NeedyMeds and similar assistance directories, which can help identify prescription support programs and savings options.
• The Alzheimer’s Association, which offers practical information on Medicare, financial planning, and dementia care support.
• The Medicare GUIDE Model, a program that can provide dementia care navigation services for eligible people.

Questions to ask before starting treatment

Before starting any Alzheimer’s medication, families should ask a few practical questions:

• What is the goal of this medication: symptom relief, slower decline, or agitation control?
• What stage of disease is this drug meant for?
• What side effects should we expect in the first month?
• How will we know if it is helping?
• Do we need MRI scans, blood work, or infusion visits?
• Will this be billed under Part B, Part D, or another insurance benefit?
• Are there lower-cost alternatives, generic options, or assistance programs?

Those questions can save money, time, and a surprising amount of panic.

Bottom line

Medications used to treat Alzheimer’s disease now include more than the classic memory drugs. Symptom-focused treatments such as donepezil, rivastigmine, galantamine, and memantine still matter, especially because they are familiar and practical. Newer anti-amyloid therapies such as lecanemab and donanemab offer another option for carefully selected patients with early disease, though they come with more monitoring, more complexity, and more coverage questions. Brexpiprazole also adds an important option for agitation related to Alzheimer’s dementia.

Financial help exists, but families usually need to be proactive to find it. Medicare plan review, Extra Help, payment spreading options, manufacturer assistance programs, and counseling services can all make treatment more affordable. The best approach is usually part medicine, part planning, and part persistence.

That may not sound glamorous, but in Alzheimer’s care, practical wins count. A medication that helps someone stay steady a little longer, a plan that trims a large monthly bill, or a counselor who helps untangle coverage rules can all make a meaningful difference in daily life.

Experience-based insights from families navigating Alzheimer’s medications and costs

In real life, the journey with Alzheimer’s medication rarely feels as tidy as a chart in a clinic brochure. Many families say the first prescription brings a strange mix of hope and realism. Hope, because doing something feels better than doing nothing. Realism, because most caregivers quickly learn that Alzheimer’s medications usually do not create dramatic movie-scene turnarounds where a loved one suddenly remembers everyone’s birthday and starts balancing the checkbook again. What they often do, when they help, is quieter. A person may seem a little more engaged at breakfast, a little less confused in the evening, or a little more capable of following a familiar routine.

That subtlety can make treatment emotionally complicated. Some caregivers feel disappointed because the improvement is not obvious. Others feel relieved because even a small stabilization can be huge in everyday life. Being able to dress with fewer prompts, stay calmer during appointments, or hold onto toileting independence for longer can ease both emotional strain and caregiving workload. Those changes may not look dramatic from the outside, but families living the routine know they matter.

Another common experience is trial and adjustment. A medication may seem promising until nausea, poor appetite, dizziness, or sleep problems show up. Families often describe a period of detective work: is this the disease progressing, a side effect, dehydration, poor sleep, or three problems showing up to the same party? This is one reason close follow-up matters. Sometimes a lower dose, slower titration, patch formulation, or medication switch makes the plan more tolerable.

Costs also shape the experience more than many people expect. Families often assume that once a doctor prescribes a medicine, the hardest part is over. Then the insurance calls begin. One plan may cover a drug but require prior authorization. Another may place it on a high tier. A newer infusion-based therapy may bring separate questions about MRI scans, registry participation, coinsurance, and where treatment can be administered. Caregivers frequently say that learning the coverage system feels like taking an unpaid second job.

Still, there is a pattern among families who manage this well: they ask questions early, keep records, and use help that is already available. They call SHIP counselors. They compare formularies during open enrollment. They ask the neurologist’s office about manufacturer programs. They check whether Extra Help, Medicare savings support, or patient assistance might apply. They keep copies of denials, appeals, and enrollment forms. None of that is glamorous, but it works.

Perhaps the most honest real-world lesson is this: treatment success is not only about the drug. It is about fit. The best medication plan is the one that matches the person’s stage of disease, safety profile, home support, finances, and goals of care. For some families, that means pursuing a newer therapy aggressively. For others, it means choosing a simpler, lower-cost regimen that causes fewer side effects and preserves daily comfort. Both paths can be thoughtful, loving, and medically reasonable.